Region
Featured experience
Pony AI $413 million IPO
We advised Pony AI on its IPO, concurrent private placements and Nasdaq listing
Horizon Robotics HK$5.41 billion IPO
We advised Horizon Robotics on its IPO and HKEX listing
CK Hutchison Holdings $2 billion notes offering
We advised CK Hutchison Holdings on its Rule 144A / Regulation S notes offering
Hollysys Automation $1.66 billion acquisition by Ascendent Capital Partners
We are advising Hollysys on the acquisition
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Tencent Music Entertainment Group secondary listing
We advised Tencent Music Entertainment Group on its secondary listing by way of introduction on the HKEX
Interra Acquisition HK$1 billion IPO
We advised the SPAC on its IPO and HKEX listing
Tencent €300 million investment in Ubisoft
We are advising Tencent on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Red Star Macalline Group $249.7 million credit enhanced bonds offering
We advised the issuer on the credit enhanced bonds offering
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Taibang Biologic Group $300 million equity raising
We are advising Taibang Biologic Group in connection with its equity raising by a group of investors
Akeso HK$582 million share placement
We advised Akeso in the placement of new shares